ClinicalTrials.gg
RecruitingNCT07201922Updated Nov 13, 2026

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

A Phase 3 interventional study of Nerandomilast and Placebo in Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities and Interstitial Lung Diseases, sponsored by Boehringer Ingelheim. Recruiting at 55 sites in 13 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 13, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim — 4 open to participants now, 6 under way, 4 of them phase 3. Lung Diseases, Interstitial · Boehringer Ingelheim.

Planned enrollment
8th of 12
80 · median 248
Started
2026
with 2 others
Phase 3
11 of 24
3 open now
Registered
22nd of 24
by date

Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 3, and was the 22nd registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

4 of the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, or all of them as a file.
02

Study summary

This study is open to people aged 40 years or older who have at least 1 family member with pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes scarred, making it harder to breathe. People can join if a lung scan shows early changes in the lung, called interstitial lung abnormalities, which may lead to lung scarring. People with family members who have pulmonary fibrosis are more likely to develop it themselves. That is why it is important to check early for lung changes and find ways to prevent the condition from getting worse. The purpose of this study is to find out whether a medicine called nerandomilast can help slow down changes in the lung in people with a family history of pulmonary fibrosis.

Participants are put into one of 2 groups randomly, which means the group is chosen by chance. One group takes nerandomilast tablets, and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet twice a day for about 2 to 3 years. There is a 3 out of 5 chance that participants will receive nerandomilast instead of the placebo.

Participants are in the study for about 2 to 3 years. Participants visit the study site multiple times: more frequently during the first 2 years (about every 3 months), and then every 6 months thereafter. In the 3rd year, participants also have phone calls with the site staff every 3 months.

Doctors regularly test lung function and take chest scans to see if the treatment works. The results are compared between the 2 groups to see if nerandomilast helps. The doctors also check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Familial Pulmonary Fibrosis
  • Interstitial Lung Abnormalities
  • Interstitial Lung Diseases
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals ≥40 years of age at the time of first signed at Visit 1a
  • Participants must have at least 1 first-degree relative (biological parent, sibling, or child) with confirmed pulmonary fibrosis (idiopathic pulmonary fibrosis [IPF], idiopathic nonspecific interstitial pneumonia [NSIP], and/or pulmonary fibrosis due to known genetic cause [e.g. short telomere syndrome, mucin 5B (MUC5B) mutation, surfactant protein mutations])
  • High resolution computed tomography (HRCT) scan with evidence of interstitial lung abnormalities involving at least 5% of a single lung zone or interstitial lung disease (ILD), based on central evaluation
  • Forced vital capacity (FVC) ≥80% of predicted normal at Visit 1b
  • Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for ≥70% of predicted normal at Visit 1b Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Prior known pulmonary fibrosis that, in the opinion of the Investigator, requires treatment with approved therapies
  • Prebronchodilator (FEV1)/FVC \<0.7 at Visit 1b
  • HRCT findings consistent with probable or definite usual interstitial pneumonia (UIP) pattern
  • Any medical condition that is known to predispose to the development of pulmonary fibrosis (e.g. known connective tissue disease)
  • Prior or current use of nerandomilast, nintedanib, or pirfenidone Further exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Nerandomilast

    Drug: Nerandomilast

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Nerandomilast

    Also known as: BI 1015550, JASCAYD®

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Time to physiologic or radiologic worsening of ILA/ILD over the whole trial

    Defined as relative decline in forced vital capacity (FVC) % predicted of \>10% from baseline; or absolute decline in diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted \>10% from baseline; or absolute increase in weighted reticulovascular score (wRVS) \>2% and total disease extent (TDE) \>2.5% on chest high resolution CT scan (HRCT), as measured by e-Lung Quantitative HRCT scoring, from baseline

    Time frame: up to 164 weeks

Secondary outcomes

  1. Absolute change from baseline in wRVS on e-Lung Quantitative HRCT scoring at weeks 26, 52, and 104

    Time frame: at baseline, at weeks 26, 52 and 104

  2. Absolute change from baseline in TDE on e-Lung Quantitative HRCT scoring at weeks 26, 52, and 104

    Time frame: at baseline, at weeks 26, 52 and 104

  3. Absolute change from baseline in FVC (% predicted) at weeks 26, 52, and 104

    Time frame: at baseline, at weeks 26, 52 and 104

  4. Absolute change from baseline in DLCO (% predicted) at weeks 26, 52, and 104

    Time frame: at baseline, at weeks 26, 52 and 104

  5. Time to relative decline from baseline in FVC (% predicted) of >10% over 52 weeks and over the whole trial

    Time frame: up to 164 weeks

  6. Time to absolute decline from baseline in FVC (% predicted) of >5% over 52 weeks and over the whole trial

    Time frame: up to 164 weeks

  7. Time to absolute decline from baseline in DLCO (% predicted) of >10% over 52 weeks and over the whole trial

    Time frame: up to 164 weeks

  8. Time to absolute increase in wRVS >2% and TDE >2.5% on chest HRCT, as measured by e-lung quantitative HRCT scoring over 52 weeks and over the whole trial

    Time frame: up to 164 weeks

  9. Time to physiologic or radiologic worsening of ILA/ILD over 52 weeks

    Time frame: up to 52 weeks

07

Study locations

54 of 55 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2029, 39 months after the start.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's planned 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 1, 2025
StartActual
Feb 10, 2026
Primary completionEst.
May 14, 2029
CompletionEst.
May 23, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed. 5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • McGill University Health Centre (MUHC) · Montreal, CanadaNot yet recruiting→Recruiting
  • Hospital Universitario De La Princesa · Madrid, SpainNot yet recruiting→Recruiting
  • Kanagawa Cardiovascular and Respiratory Center · Kanagawa, Yokohama, JapanActive, not recruiting→Recruiting
  • Vanderbilt University Medical Center · Nashville, United StatesNot yet recruiting→Recruiting
  • St. Joseph's Healthcare Hamilton · Hamilton, CanadaNot yet recruiting→Recruiting
Show 3 added (2 Spain, 1 Argentina)
  • Fundacion NIBA Neurologia Infantil Buenos Aires · CABA, Argentina
  • Hospital Virgen del Rocio · Seville, Spain
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 3 removed
  • CEDIC - Centro de Investigacion Clinica · CABA, Argentina
  • Hospital Virgen del Rocío · Seville, Spain
  • Hospital Virgen del Rocio · Seville, Spain
across 3 updates, Sep 30, 2026 – Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Kanagawa Cardiovascular and Respiratory Center · Kanagawa, Yokohama, JapanContact added n•••@bitrialsupport.com · •••8862
Oct 28, 2026
Show all 3 updates
  1. Nov 13, 2026
    1 site added, 1 site removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Vanderbilt University Medical Center · Nashville, United StatesNot yet recruiting→Recruiting
    • St. Joseph's Healthcare Hamilton · Hamilton, CanadaNot yet recruiting→Recruiting
    Show site
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 1 removed
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Oct 28, 2026
    Kanagawa Cardiovascular and Respiratory Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Kanagawa Cardiovascular and Respiratory Center · Kanagawa, Yokohama, JapanContact added n•••@bitrialsupport.com · •••8862
    + 2 other changes: identifiers and verification date
  3. Sep 30, 2026
    2 sites added, 2 sites removed. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • McGill University Health Centre (MUHC) · Montreal, CanadaNot yet recruiting→Recruiting
    • Hospital Universitario De La Princesa · Madrid, SpainNot yet recruiting→Recruiting
    Show 2 added (1 Argentina, 1 Spain)
    • Fundacion NIBA Neurologia Infantil Buenos Aires · CABA, Argentina
    • Hospital Virgen del Rocio · Seville, Spain
    Show 2 removed
    • CEDIC - Centro de Investigacion Clinica · CABA, Argentina
    • Hospital Virgen del Rocío · Seville, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07201922
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Feb 10, 2026
Primary completion
May 14, 2029 (estimated)
Completion
May 23, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion